Archives of Gynecology and Obstetrics

, Volume 282, Issue 5, pp 507–514 | Cite as

Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis

  • Adolf E. Schindler
  • Alexandra Henkel
  • Claudia Moore
  • Michael Oettel
General Gynecology



Hormonal treatment of endometriosis is often continued for long periods and has the potential to affect many essential metabolic processes. The current study aimed to determine the effects and safety of high-dose dienogest as a medical endometriosis therapy.


The effects and safety of high-dose dienogest, 20–30 mg/day for 24 weeks, were examined in 21 women aged 18–52 years with laparoscopically and histologically proven endometriosis stage I–IV (according to revised American Society of Reproductive Medicine criteria). At baseline and week 24, sera were obtained and stored at −20°C prior to analysis.


The study showed no clinically significant effect of high-dose dienogest on thyroid or adrenal function, electrolyte balance or haematopoiesis. High-dose dienogest therapy also had no appreciable effects on glucose and lipid metabolism, liver enzymes or haemostasis. For instance, although dienogest mediated small increases in the haemostatic variables prothrombin fragment 1 + 2, antithrombin III and protein C, final levels (at week 24) remained within normal reference ranges for these parameters. The exception was the HDL-3 cholesterol concentration at week 24 (0.97 mmol/l), which increased beyond the normal range of 0.28–0.64 mmol/l.


This investigation yielded a unique dataset on the safety of high-dose dienogest in endometriosis stage I–IV. High-dose dienogest (20–30 mg/day) had little influence upon all the parameters measured. It is therefore likely that lower doses of dienogest would have similarly neutral safety effects: an important consideration in the use of dienogest for the treatment of endometriosis.


Endometriosis Dienogest Progestogen Lipids Laboratory parameters Haemostasis 


Conflict of interest statement

The authors declare that they have no conflict of interest.


  1. 1.
    Eskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24:235–258CrossRefPubMedGoogle Scholar
  2. 2.
    Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R et al (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20:2698–2704CrossRefPubMedGoogle Scholar
  3. 3.
    Mahutte NG, Kayisli U, Arici A (2005) Endometriosis is an inflammatory disease. In: Olive D (ed) Endometriosis in clinical practice. Taylor and Francis, Oxford, pp 79–88Google Scholar
  4. 4.
    Schindler AE (2004) Pathophysiology, diagnosis and treatment of endometriosis. Minerva Ginecol 56:419–435PubMedGoogle Scholar
  5. 5.
    European Progestin Club (1996) Progestins: present and future. J Steroid Biochem Mol Biol 59:357–363 (editorial)CrossRefGoogle Scholar
  6. 6.
    Schindler AE (2003) Differential effects of progestins. Maturitas 46(Suppl 1):S3–S5CrossRefPubMedGoogle Scholar
  7. 7.
    Oettel M, Carol W, Elger W (1995) A 19-norprogestin without 17β-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 31:517–536Google Scholar
  8. 8.
    Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K et al (2008) Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 73:222–231CrossRefPubMedGoogle Scholar
  9. 9.
    Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW et al (2003) Classification and pharmacology of progestins. Maturitas 46(Suppl 1):S7–S16CrossRefPubMedGoogle Scholar
  10. 10.
    Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A et al (2002) Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 77:684–692CrossRefPubMedGoogle Scholar
  11. 11.
    Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H et al (2009) Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91:675–681CrossRefPubMedGoogle Scholar
  12. 12.
    Köhler G, Göretzlehner G, Amon I (1987) Therapy of endometriosis with dienogest. Zentralbl Gynakol 109:795–801 (in German)PubMedGoogle Scholar
  13. 13.
    Momoeda M, Taketani Y (2007) Randomized double-blind, multicentre, parallel-group dose–response study of dienogest in patients with endometriosis. Jpn Pharmacol Ther 35:769–783Google Scholar
  14. 14.
    Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of dienogest 1, 2, and 4 mg daily in endometriosis. Int J Gynecol Obstet 108:21–25CrossRefGoogle Scholar
  15. 15.
    Schindler AE, Christensen B, Henkel A, Oettel M, Moore C (2006) High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol Endocrinol 22:9–17CrossRefPubMedGoogle Scholar
  16. 16.
    Schindler AE, Henkel A, Christensen B, Oettel M, Moore C (2009) Dienogest and the breast. Gynecol Endocrinol 25:472–474CrossRefPubMedGoogle Scholar
  17. 17.
    Godsland IF (1996) The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med Suppl 738:1–60PubMedGoogle Scholar
  18. 18.
    Selman PJ, Mol JA, Rutteman GR, Rijnberk A (1994) Progestin treatment in the dog. I. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis. Eur J Endocrinol 131:413–421CrossRefPubMedGoogle Scholar
  19. 19.
    Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A (1990) Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynecol Reprod Biol 36:97–105CrossRefPubMedGoogle Scholar
  20. 20.
    Winkler UH (1996) Effects of androgens on haemostasis. Maturitas 24:147–155PubMedGoogle Scholar
  21. 21.
    Winkler U, Buhler K, Koslowski S, Oberhoff C, Schindler AE (1992) Plasmatic haemostasis in gonadotrophin-releasing hormone analogue therapy: effects of leuprorelin acetate depot on coagulatory and fibrinolytic activities. Clin Ther 14(Suppl A):114–120PubMedGoogle Scholar
  22. 22.
    Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H (2004) Effect of four oral contraceptives on hemostatic parameters. Contraception 70:97–106CrossRefPubMedGoogle Scholar
  23. 23.
    Schweppe KW, Ebert C, Cirkel U (1988) Effects of danazol therapy in endometriosis on the blood picture and blood coagulation. Geburtshilfe Frauenheilkd 48:634–636 (in German)CrossRefPubMedGoogle Scholar
  24. 24.
    Hoetzer GL, Stauffer BL, Greiner JJ, Casas Y, Smith DT, DeSouza CA (2003) Influence of oral contraceptive use on endothelial t-PA release in healthy premenopausal women. Am J Physiol Endocrinol Metab 284:E90–E95PubMedGoogle Scholar
  25. 25.
    Palomba S, Russo T, Orio F Jr, Sammartino A, Sbano FM, Nappi C et al (2004) Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Hum Reprod 19:415–421CrossRefPubMedGoogle Scholar
  26. 26.
    Mattsson L, Cullberg G, Samsioe G (1982) Influence of esterified estrogens and medroxyprogesterone on lipid metabolism and sex steroids. A study in oophorectomized women. Horm Metab Res 14:602–606CrossRefPubMedGoogle Scholar
  27. 27.
    Fahraeus L, Sydsjo A, Wallentin L (1986) Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 45:503–506PubMedGoogle Scholar
  28. 28.
    Fahraeus L, Larsson-Cohn U, Ljungberg S, Wallentin L (1984) Plasma lipoproteins during and after danazol treatment. Acta Obstet Gynecol Scand Suppl 123:133–135CrossRefPubMedGoogle Scholar
  29. 29.
    Grimes DA, Lobo RA (2002) Perspectives on the Women’s Health Initiative trial of hormone replacement therapy. Obstet Gynecol 100:1344–1353CrossRefPubMedGoogle Scholar
  30. 30.
    Hughes JK, Mendelsohn D (1999) Serum lipoprotein (a) levels in ‘normal’ individuals, those with familial hypercholesterolaemia, and those with coronary artery disease. S Afr Med J 78:567–570Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Adolf E. Schindler
    • 1
  • Alexandra Henkel
    • 2
  • Claudia Moore
    • 3
  • Michael Oettel
    • 4
  1. 1.Institute for Medical Research and EducationEssenGermany
  2. 2.Abteilung für Gynäkologie und GeburtshilfeSt Johannes-HospitalDortmundGermany
  3. 3.JenaGermany
  4. 4.JenaGermany

Personalised recommendations